Macular Edema pipeline is complete research and development history and latest news and press releases. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.
Macular Edema pipeline companies are ActiveSite Pharmaceuticals Inc, Coherus BioSciences Inc, Lupin Ltd, Mabion SA, Pfizer Inc, Promedior Inc.
Macular Edema – Drug Profiles : ACX-107, aflibercept biosimilar, ASPPDC-020, BLO-021, celecoxib, dexamethasone sodium phosphate, HO-10, PRM-167, ranibizumab biosimilar, ranibizumab biosimilar, ranibizumab biosimilar
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1057918
Pharmaceutical and Healthcare latest pipeline guide Macular Edema – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase This Macular Edema Pipeline Review H1 2017 Report of 43 Pages with Company profiles and Drugs Analysis at http://www.reportsnreports.com/purchase.aspx?name=1057918
The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 6, 2 and 1 respectively.
Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
List of Figures
Number of Products under Development for Macular Edema, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help in purchase decision by mapping your information needs with our huge collection of reports.